Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Tezepelumab-ekko (Tezspire) is recommended for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showing significant efficacy in reducing the annualized asthma exacerbation rate (AAER) and improving lung function across various studies.
• Twelve systematic reviews/meta-analyses were analyzed to evaluate Tezspire's safety and effectiveness in comparison to other biologics used in treating severe asthma.
• Tezspire has proven effective regardless of baseline eosinophil count, making it a versatile treatment option for severe asthma in a wide range of patient subgroups. This inclusivity sets it apart from other biologics like benralizumab, dupilumab, or mepolizumab, which often show increased efficacy directly tied to higher eosinophil counts.
• By targeting thymic stromal lymphopoietin (TSLP), an initial element in the inflammatory cascade, Tezspire may provide broader efficacy across Type 2-high and Type 2-low asthmas, unlike some biologics predominantly effective only against Type 2-high eosinophilic asthmas.
• Comparative analyses indicate that Tezspire and dupilumab significantly reduce exacerbations in eosinophilic asthma, with indirect comparisons suggesting comparable or slightly superior effectiveness of Tezepelumab-ekko over other drugs.
• The safety profile is favorable, as most studies report similar incidence rates of adverse events among those treated with Tezepelumab-ekko versus placebo groups; common side effects include nasopharyngitis, headache, and bronchitis, which are consistent with or slightly better than profiles seen among users of different types of biological treatments for asthma.
• Serious adverse events were not significantly higher among patients treated with Tezepelumab-ekko compared to placebo, aligning well with findings related to other biologics like dupilumab, benralizumab, and mepolizumab.
• Tezspire has demonstrated consistent benefits across a diverse array of patient subgroups, including different levels of eosinophils and allergic status, making it potentially more universally applicable for severe asthma treatment. This contrasts with some biologics whose efficacy may diminish or become conditional upon certain inflammatory profiles or eosinophil thresholds.